Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMC

Intraindividual Variation in Markers of Intestinal Permeability and Adipose Tissue Inflammation in Healthy Normal-Weight to Obese Adults

Kuzma JN., Hagman DK., Cromer G., Breymeyer KL., Roth CL., Foster-Schubert KE.

Clinical Trial with a reported sample of 12 on Hip, published in Cancer Epidemiol Biomarkers Prev (2019) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Cancer Epidemiol Biomarkers Prev (2019)
Reported sample size
12
Source database
Europe PMC
PMID
30573517
PMCID
PMC6401228
DOI
10.1158/1055-9965.epi-18-0641
Citations
18

Abstract (original English)

Background Intestinal permeability and adipose tissue inflammation are considered mechanistic links in the relationship between diet, obesity, and chronic disease. However, methods to measure both are not well standardized, and the reliability of commonly used measures is not known. Methods We calculated the intraclass correlation coefficient (ICC) for several common measures of intestinal permeability and adipose tissue inflammation from a randomized clinical trial of cross-over design in which normal-weight ( n = 12) or overweight/obese ( n = 12) individuals each completed three 8-day dietary intervention periods. Results For biomarkers of intestinal permeability, plasma zonulin, and lipopolysaccharide-binding protein, ICCs were "excellent" (i.e., >0.9). The direct measure of intestinal permeability, the lactulose/mannitol test, exhibited "fair" reliability (ICC = 0.53). A wider range of ICCs (0.6-0.9), suggesting "good" to "excellent" reliability, were obtained for measures of adipose tissue expression of genes encoding major mediators of inflammation. Similarly, individual immune cell populations isolated from adipose tissue, expressed as a percentage of all CD45 + cells, also had "good" to "excellent" ICCs. However, when these populations were expressed as number of cells per gram of tissue, ICC values were "fair," falling below 0.6. Conclusions Due to the repeated measure

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
IntestinesAdipose TissueHumansObesityInflammationAcute-Phase ProteinsHaptoglobinsCarrier ProteinsMembrane GlycoproteinsProtein Precursors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research